Education
About Us
Working with TipRanks
Follow Us
NeoGenomics Inc. (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
$12.47
$0.52(2.83%)
At close: 4:00 PM EST
$12.47
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $15.26
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.78M
Market Cap
$1.61B
Enterprise Value$569.59M
Total Cash (Recent Filing)$164.12M
Total Debt (Recent Filing)$410.31M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 17, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,387,800
10 Day Avg. Volume2,192,158
30 Day Avg. Volume1,779,569
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)0.46
Price to Sales (P/S)0.63
P/FCF Ratio-12.26
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit1.85
Enterprise Value/Ebitda-14.17
Forecast
1Y Price Target
$14.00Price Target Upside12.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.17
Revenue Forecast (FY)$795.98M
Bulls Say, Bears Say
Bulls Say
Leadership TransitionAppointment of an experienced chief financial officer with prior CFO and senior finance roles could restore forecasting credibility and improve investor confidence in the company's execution.
Operational And Testing GrowthSustained growth in Next‑Generation Sequencing tests alongside a planned unified laboratory information system is expected to improve operational efficiency and support clinical revenue expansion.
Product Launch And ReimbursementMolDX reimbursement approval combined with a favorable court ruling clears the path for a clinical launch of the RaDaR ST MRD assay, creating a potential new revenue stream in oncology.
Bears Say
Margin Pressure From AcquisitionAdjusted gross margins were pressured by costs associated with the Pathline acquisition, weighing on profitability and operating margin expansion.
Non‑clinical Revenue WeaknessDiscontinuation of an earlier RaDaR product and softer biopharma testing demand are keeping non‑clinical revenue depressed, limiting diversification of the revenue base.
Revenue Timing Risk From Pharma ActivityRecognition of revenue from samples run for pharmaceutical customers is expected to be delayed into the first quarter of 2026, creating near‑term top‑line timing uncertainty.
NeoGenomics News
NEO FAQ
What was NeoGenomics Inc.’s price range in the past 12 months?
NeoGenomics Inc. lowest stock price was $4.72 and its highest was $15.26 in the past 12 months.
What is NeoGenomics Inc.’s market cap?
NeoGenomics Inc.’s market cap is $1.61B.
When is NeoGenomics Inc.’s upcoming earnings report date?
NeoGenomics Inc.’s upcoming earnings report date is Feb 17, 2026 which is in 19 days.
How were NeoGenomics Inc.’s earnings last quarter?
NeoGenomics Inc. released its earnings results on Oct 28, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.009.
Is NeoGenomics Inc. overvalued?
According to Wall Street analysts NeoGenomics Inc.’s price is currently Undervalued.
Does NeoGenomics Inc. pay dividends?
NeoGenomics Inc. pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics Inc. dividends here
What is NeoGenomics Inc.’s EPS estimate?
NeoGenomics Inc.’s EPS estimate is 0.04.
How many shares outstanding does NeoGenomics Inc. have?
NeoGenomics Inc. has 129,387,800 shares outstanding.
What happened to NeoGenomics Inc.’s price movement after its last earnings report?
NeoGenomics Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NeoGenomics Inc.?
Currently, no hedge funds are holding shares in NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (12.27% Upside)
$14.00 (12.27% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $276.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.08%
12-Months-Change
Fundamentals
Return on Equity
-12.99%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
NeoGenomics Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Company Deck
NEO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance in the clinical segment, driven by volume and revenue growth, successful acquisitions, and favorable legal outcomes. However, challenges remain in nonclinical revenue, particularly in pharma, which are expected to persist into 2026.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$14.00
▲(12.27% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
24.20% Mutual Funds
0.12% Other Institutional Investors
50.28% Public Companies and
Individual Investors